Moderna pays up to $2.25bn to settle drug delivery tech patent lawsuit

Core Insights - Moderna has agreed to pay up to $2.25 billion to settle a patent infringement lawsuit with Genevant and Arbutus, concluding a lengthy legal dispute between the companies [1][2][3] Settlement Details - The settlement includes an upfront payment of $950 million, with a potential additional payment of $1.3 billion contingent on the outcome of a pending appeal in the US Court of Federal Claims [3] - The agreement grants Moderna a non-exclusive license to utilize Genevant and Arbutus' lipid nanoparticle (LNP) delivery technology for infectious disease applications [3] Legal Context - This settlement occurs as Genevant is involved in a similar legal dispute with Pfizer and BioNTech regarding the use of its LNP technology in their Covid-19 vaccine, Comirnaty [4] - Moderna, Pfizer, and BioNTech have been engaged in ongoing patent litigation concerning their respective mRNA technologies, with multiple lawsuits filed globally [5] Financial Outlook - Moderna's CEO, Stéphane Bancel, indicated that resolving this legal matter removes uncertainty and allows the company to focus on future growth, with expectations to return to revenue growth by 2026, ending that year with over $5 billion in cash [6] - The company aims to break even by 2028, following a reported net loss of $826 million in Q4 2025, attributed to declining Covid-19 vaccine sales and changing vaccine usage policies in the US [7] Regulatory Challenges - Moderna has faced hurdles in gaining approval for its pipeline products, including the FDA's initial refusal to review its seasonal influenza vaccine, mRNA-1010, due to trial design concerns, although this decision was later reversed [8]